Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer. 2015;121(1):25–33.
2. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush M, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373–80.
3. •• National Comprehensive Cancer Network (NCCN). NCCN guidelines version 3.2023 genetic/familial high-risk assessment: breast, ovarian, and pancreatic. NCCN clinical practice guidelines in oncology; 2023. The NCCN Guidelines provider the current evidence and recommendations for hereditary breast cancer gene risks and management. The guidelines are updated at least annually by a panel of experts, and newer versions of the guidelines can be used to find the current data and recommendations after the date of this publication.
4. Cathcart-Rake EJ, Ruddy KJ, Bleyer A, Johnson RH. Breast cancer in adolescent and young adult women under the age of 40 years. JCO Oncol Pract. 2021;17(6):305–13.
5. Daly MB, Rosenthal E, Cummings S, Bernhisel R, Kidd J, Hughes E, et al. The association between age at breast cancer diagnosis and prevalence of pathogenic variants. Breast Cancer Res Treat. 2023;199(3):617–26.